Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes

British Journal of Cancer

Volumn 110, Issue 4, 2014, Pages 976-983

  Shapira, I ^a,b   Oswald, M ^c   Lovecchio, J ^b,d   Khalili, H ^c   Menzin, A ^b,d   Whyte, J ^b,d   Dos Santos, L ^b,d   Liang, S ^b,d   Bhuiya, T ^b,d   Keogh, M ^c   Mason, C ^c   Sultan, K ^b,d   Budman, D ^a,b   Gregersen, P K ^b,c   Lee, A T ^b,c  

^a North Shore Long Island Center for Advanced Medicine   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84894386160     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.795     Document Type: Article

References (39)

1. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108: 5003-5008.
2. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C, Urban N (2010) Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study. J Natl Cancer Inst 102: 26-38.
3. Bartel DP (2009) MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233.
4. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy. Stat Soc Ser B 57: 289-300.
5. Berkenblit A, Cannistra SA (2005) Advances in the management of epithelial ovarian cancer. J Reprod Med 50: 426-438.
6. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Carey V, Redestig H. for C language enhancements. ROC: Utilities for ROC, with array focus. R package version 1.34.0 http://www.bioconductor.org.
8. Chung YW, Bae HS, Song JY, Lee JK, Lee NW, Kim T, Lee KW (2013) Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patient. Int J Gynecol Cancer 23: 673-679.
9. Concepcion CP, Bonetti C, Ventura A (2012) The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J 18: 262-267.
10. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, Gibbs RA, Sander C, Hayes DN, Gunaratne PH. Cancer Genome Atlas Research Network (2012) Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 7: E34546.
11. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, Wood III W, Becker KG, Morin PJ (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3: E2436.
12. Dahiya N, Morin PJ (2010) MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17: F77-F89.
13. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, Corsten MF, Schroen B, Lair ML, Heymans S, Wagner DR (2012) Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 58: 559-567.
14. Dutta S, Wang FQ, Phalen A, Fishman DA (2010) Biomarkers for ovarian cancer detection and therapy. Cancer Biol Ther 9: 668-677.
15. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64: 6503-6510.
16. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M (2010) Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res 16: 3954-3963.
17. Habeeb O, Goodglick L, Soslow RA, Rao RG, Gordon LK, Schirripa O, Horvath S, Braun J, Seligson DB, Wadehra M (2010) Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer 116: 4718-4726.
18. Häusler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler M, Dietl J, Wischhusen J (2010) Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer 103: 693-700.
19. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707.
20. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277-300.
21. Moyer VA (2012) Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 157: 900-904.
22. Olive V, Jiang I, He L (2010) mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42: 1348-1354.
23. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, Andriole GL, Ogden S, Ragard LR, Buys SS. PLCO Project Team (2009) Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 113: 775-782.
24. Piver MS, Malfetano J, Baker TR, Hempling RE (1992) Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatinbased chemotherapy. Gynecol Oncol 46: 357-360.
25. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD (2012) Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 72: 5945-5955.
26. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M (2012) Blood cell origin of circulating microRNAs: A cautionary note for cancer biomarker studies. Cancer Prev Res 5: 492-497.
27. Rege SD, Geetha T, Pondugula SR, Zizza CA, Wernette CM, Ramesh Babu J (2013) Noncoding RNAs in neurodegenerative diseases. ISRN Neurol 30: 375852.
28. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-Time PCR platform. Gynecol Oncol 112: 55-59.
29. Schmittgen TD, Livak KJ (2008) Analyzing real-Time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
30. Shen J, Stass SA, Jiang F (2013) MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329: 125-136.
31. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62: 10-29.
32. Smyth G (2005) Linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) pp 397-420. Springer: New York.
33. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21.
34. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39: 7223-7233.
35. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA (2006) Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 107: 90-98.
36. Weiland M, Gao XH, Zhou L, Mi QS (2012) Small RNAs have a large impact: Circulating microRNAs as biomarkers for human diseases. RNA Biol 9: 850-859.
37. Wylie D, Shelton J, Choudhary A, Adai AT (2011) A novel mean-centering method for normalizing microRNA expression from high-Throughput RT-qPCR data. BMC Res Notes 4: 555.
38. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Bützow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004-7009.
39. Zhu S, Pan W, Qian Y (2013) MicroRNA in immunity and autoimmunity. J Mol Med (Berl) 91: 1039-1050.